We work in the field of Regenerative Medicine, looking for efficient cellular therapies, with a focus on the functional rescue of neuronal activity after spinal cord injury.

In the Neuronal and Tissue Regeneration Laboratory (LRTN, in its Spanish acronym) our work is focused on the search for efficient cell therapies and adapting them to treat an increasing range of pathological processes. We also aim to translate these different treatment modalities from experimental models into clinical settings.

Our group’s primary line of research is the functional rescue of the neuronal activity lost after a spinal cord injury (SCI). SCIs are very complex and involve multiphasic processes. This has led us to prospectively design alternative cell-based treatments that combine pharmacological supplements, tissue engineering and biomaterials, electrical-magnetic stimulation, neuronal interfaces, and neurorehabilitation approaches, with the ultimate objective of favoring neuroplasticity and producing functional results.

At the preclinical level, our overriding goal is the efficient translation of the therapies we are developing into clinical practice. We are also working closely with different reference hospitals for translational research (Hospital La Fe and Hospital Casa de la Salud in Valencia, and Hospital Vall de Hebron in Barcelona) to further our aim of achieving bench to bedside medicine.

Presentation

Get to know us better

Research Staff

The people who make it all possible

M Victoria Moreno Manzano
vmorenom@cipf.es

Guillem Paniagua Soriano
gpaniagua@cipf.es

Eric López Mocholi
elopezm@cipf.es

Ana López Rodríguez
alopezr@cipf.es

Loris Mannino 
lmannino@cipf.es

Maria Del Mar Sánchez Martín
mmsanchez@cipf.es

Samuel Martín Pérez
smartin@cipf.es

Publications

Our scientific contributions

Chondroitin sulfate proteoglycans prevent immune cell phenotypic conversion and inflammation resolution via TLR4 in rodent models of spinal cord injury.
Francos-Quijorna I, Sánchez-Petidier M, Burnside ER, Badea SR, Torres-Espin A, Marshall L, de Winter F, Verhaagen J, Moreno-Manzano V and Bradbury EJ
Nature Communications, 2022 May,  DOI:  10.1038/s41467-022-30467-5,  Vol. 13,  pag. 2933-2933

Toll-like receptors 2 and 4 differentially regulate the self-renewal and differentiation of spinal cord neural precursor cells.
Sanchez-Petidier M, Guerri C and Moreno-Manzano V
Stem Cell Research & Therapy, 2022 Mar,  DOI:  10.1186/s13287-022-02798-z,  Vol. 13,  pag. 117-117

A rationally designed self-immolative linker enhances the synergism between a polymer-rock inhibitor conjugate and neural progenitor cells in the treatment of spinal cord injury.
Giraldo E, Nebot VJ, Ðordevic S, Requejo-Aguilar R, Alastrue-Agudo A, Zagorodko O, Armiñan A, Martinez-Rojas B, Vicent MJ and Moreno-Manzano V
BIOMATERIALS, 2021 Sep,  DOI:  10.1016/j.biomaterials.2021.121052,  Vol. 276,  pag. 121052-121052

Engineered axon tracts within tubular biohybrid scaffolds
L. DOBLADO, C. MARTINEZ-RAMOS, J. GARCIA-VERDUGO, V. MORENO-MANZANO and M. PRADAS
Journal of Neural Engineering, 2021 Aug,  DOI:  10.1088/1741-2552/ac17d8,  Vol. 18,  pag. 

Human-Induced Neural and Mesenchymal Stem Cell Therapy Combined with a Curcumin Nanoconjugate as a Spinal Cord Injury Treatment
P. BONILLA, J. HERNANDEZ, E. GIRALDO, M. GONZALEZ-PEREZ, A. ALASTRUE-AGUDO, H. ELKHENANY, M. VICENT, X. NAVARRO, M. EDEL and V. MORENO-MANZANO
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021 Jun,  DOI:  10.3390/ijms22115966,  Vol. 22,  pag. 

FUNDING

Thank you for supporting us